Vertex Pharmaceuticals, Inc. (VRTX) Company Profile & Statistics

Vertex Pharmaceuticals, Inc.
VRTX
(Nasdaq - US)
N/A
397.89
-2.87 (-0.72%)
in:usd•As of: Apr 25, 2024 15:59 UTC -4
Open
402.57
High
404.23
Low
393.26

About Vertex Pharmaceuticals, Inc.

CEO

Reshma Kewalramani

Headquarters

50 northern avenue

boston, ma 02210, united states

Auditor

Ernst & Young LLP

Employees

5,400

Share Holders

106

Website

www.vrtx.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.

Vertex Pharmaceuticals, Inc. Statistics

Valuation Measures

Market Capitalization ²	102.84B
Enterprise Value	92.85B
Enterprise Value/EBITDA (ttm)	23.13
Price to Earnings Ratio (ttm)	30.13
Price to Book (mrq)	5.93
Price to Sales (ttm)	10.60
Price to Cash (ytd)	27.63

Profitability

Gross Margin (ttm)	87.23%
Operating Margin (ttm)	35.51%
Profit Margin (ttm)	36.59%
Return on Equity (ttm)	21.91%
Return on Invested Capital (ttm)	22.00%
Return on Assets (ttm)	16.73%

Income Statement

Revenue (ttm)	9.87B
Revenue Per Share (ttm)	38.21
Gross Profit (ttm)	8.61B
EBITDA (ttm)³	4.01B
Net Income Avi to Common (ttm)	3.62B
Diluted EPS (ttm)	13.89

Share Statistics

Beta (5Y Monthly)	0.35
52-Week Change	23.07%
S&P500 52-Week Change	24.47%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	258.31M
Dividend Yield	0.00%
Float ⁴	257.94M
% Held by Insiders	0.20%
% Held by Institutions	90.96%

Balance Sheet

Total Cash (mrq)	11.22B
Total Cash Per Share (mrq)	43.43
Total Debt (mrq)	376.10M
Total Debt/Equity (mrq)	2.14%
Current Ratio (mrq)	3.99%
Quick Ratio (mrq)	3.78%
Book Value Per Share (mrq)	68.22

Cash Flow

Operating Cash Flow Per Share (ytd)	13.58
Free Cash Flow (ytd)	3.34B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Vertex Pharmaceuticals, Inc.

Trade With A Regulated Broker